Investors
Overview

Investors Overview

Company Profile

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Press Releases
Read more
Recent/Upcoming Events
Sep 10, 2024 at 1:45 PM CEST
Annual Meeting of the European Association for the Study of Diabetes (EASD)

Presentation Title: Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity: results of a phase 2, MRI-based body composition sub-study
(Session 038, Oral Presentation 557)

Speaker: Sarah Browne, M.D., Vice President, Clinical Development, Altimmune

 

Jun 25, 2024 at 9:10 AM EDT
The 7th Global MASLD Congress

Presentation Title: Role of glucagon-containing dual and triple agonists in the treatment of obesity and MASH

Speaker: Dr. Scott Harris, Chief Medical Officer, Altimmune

View all

Corporate Governance

Corporate Presentation
 

Investor Contact

Email: ir@altimmune.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe